Aeter­na dis­con­tin­ues vac­cine de­vel­op­ment; Idera re­brands as Ac­er­a­gen

As biotechs start to de­tail 2023 plans — M&A, new em­phases in drug R&D and more with in­vestors — oth­ers are start­ing to trim back or us­ing the new year as an op­por­tu­ni­ty to do an about-face and try and start with a clean slate.

Three such biotechs un­veiled next steps for their re­spec­tive com­pa­nies Tues­day morn­ing.

Aeter­na ax­es ear­ly-stage vac­cine pipeline af­ter reac­quir­ing re­gion­al rights to sole prod­uct

Aeter­na Zen­taris is cut­ting its work on a vac­cine plat­form, which the biotech said had po­ten­tial ap­pli­ca­tions against chlamy­dia and Covid-19. How­ev­er, the com­pa­ny said it had not been able to se­lect a clin­i­cal de­vel­op­ment can­di­date for a Covid-19 vac­cine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.